476 related articles for article (PubMed ID: 9129041)
21. Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment.
Shinjo K; Takeshita A; Sahara N; Kobayashi M; Nakamura S; Shigeno K; Naito K; Maekawa M; Ohnishi K; Ohno R
Intern Med; 2005 Aug; 44(8):818-24. PubMed ID: 16157979
[TBL] [Abstract][Full Text] [Related]
22. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T
Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
[TBL] [Abstract][Full Text] [Related]
23. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
24. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
[TBL] [Abstract][Full Text] [Related]
25. [In vitro study on arsenic trioxide-induced apoptosis of retinoic acid resistant acute promyelocytic leukemia cell line(MR-2)].
Cai X; Jia P; Shi X
Zhonghua Xue Ye Xue Za Zhi; 1998 Jul; 19(7):339-41. PubMed ID: 11189513
[TBL] [Abstract][Full Text] [Related]
26. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
[TBL] [Abstract][Full Text] [Related]
27. Chloroquine aggravates the arsenic trioxide (As2O3)-induced apoptosis of acute promyelocytic leukemia NB4 cells via inhibiting lysosomal degradation in vitro.
Liu DM; Zhang XD; Yang L
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6412-6421. PubMed ID: 30338810
[TBL] [Abstract][Full Text] [Related]
28. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
Kitamura K; Minami Y; Yamamoto K; Akao Y; Kiyoi H; Saito H; Naoe T
Leukemia; 2000 Oct; 14(10):1743-50. PubMed ID: 11021749
[TBL] [Abstract][Full Text] [Related]
29. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Zhang W; Ohnishi K; Shigeno K; Fujisawa S; Naito K; Nakamura S; Takeshita K; Takeshita A; Ohno R
Leukemia; 1998 Sep; 12(9):1383-91. PubMed ID: 9737686
[TBL] [Abstract][Full Text] [Related]
30. [Experimental study of low dose arsenic trioxide in treatment of patients with acute promyelocytic leukemia].
Jia PM; Zhu Q; Yu Y; Chen GQ; Chen SJ; Chen Z; Wang ZY; Tong JH
Ai Zheng; 2002 Apr; 21(4):337-40. PubMed ID: 12452006
[TBL] [Abstract][Full Text] [Related]
31. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk.
Zhu Q; Zhang JW; Zhu HQ; Shen YL; Flexor M; Jia PM; Yu Y; Cai X; Waxman S; Lanotte M; Chen SJ; Chen Z; Tong JH
Blood; 2002 Feb; 99(3):1014-22. PubMed ID: 11807007
[TBL] [Abstract][Full Text] [Related]
32. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents.
Zhu J; Guo WM; Yao YY; Zhao WL; Pan L; Cai X; Ju B; Sun GL; Wang HL; Chen SJ; Chen GQ; Caen J; Chen Z; Wang ZY
Leukemia; 1999 Jul; 13(7):1062-70. PubMed ID: 10400422
[TBL] [Abstract][Full Text] [Related]
33. Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells.
Müller S; Miller WH; Dejean A
Blood; 1998 Dec; 92(11):4308-16. PubMed ID: 9834237
[TBL] [Abstract][Full Text] [Related]
34. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of action of all-trans retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia.
Wang ZY
Gan To Kagaku Ryoho; 2002 Feb; 29 Suppl 1():214-8. PubMed ID: 11890109
[TBL] [Abstract][Full Text] [Related]
36. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
37. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells.
Giannì M; Koken MH; Chelbi-Alix MK; Benoit G; Lanotte M; Chen Z; de Thé H
Blood; 1998 Jun; 91(11):4300-10. PubMed ID: 9596679
[TBL] [Abstract][Full Text] [Related]
38. Arsenic trioxide, a therapeutic agent for APL.
Zhang TD; Chen GQ; Wang ZG; Wang ZY; Chen SJ; Chen Z
Oncogene; 2001 Oct; 20(49):7146-53. PubMed ID: 11704843
[TBL] [Abstract][Full Text] [Related]
39. Arsenic trioxide: mechanisms of action.
Davison K; Mann KK; Miller WH
Semin Hematol; 2002 Apr; 39(2 Suppl 1):3-7. PubMed ID: 12012315
[TBL] [Abstract][Full Text] [Related]
40. Arsenic trioxide: acute promyelocytic leukemia and beyond.
Bachleitner-Hofmann T; Kees M; Gisslinger H
Leuk Lymphoma; 2002 Aug; 43(8):1535-40. PubMed ID: 12400595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
